Palivizumab Drug Aliquot | Anti-RSVproteinF | Therapeutic Antibody

Aliquoted from the original reference drug | Now available for research use

Aliquots of the reference drug Palivizumab are now available as research consumables.

Palivizumab drug aliquots can be used for in vitro or in vivo experiments. For biosimilar development, different batches of Palivizumab drug can be ordered at the same time. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Synagis Palivizumab Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Synagis®/ Palivizumab Reference Product

Drug nameSynagis®
INNPalivizumab
API typePalivizumab is a recombinant humanised monoclonal antibody produced by DNA technology in mouse myeloma host cells.
Pharmacotherapeutic group
Immune sera immunoglobulins, specific immunoglobulins
ATC code
J06BB16
Target of antibody
RSV protein F
General functionPalivizumab is a humanised IgG1 monoclonal antibody directed to an epitope in the A antigenic site of the fusion protein of respiratory syncytial virus (RSV). This humanised monoclonal antibody is composed of human (95%) and murine (5%) antibody sequences. It has potent neutralising and fusion-inhibitory activity against both RSV subtype A and B strains.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Palivizumab is a humanised IgG1κ monoclonal antibody directed to an epitope in the A antigenic site of the fusion protein of respiratory syncytial virus (RSV). This humanised monoclonal antibody is composed of human (95%) and murine (5%) antibody sequences. It has potent neutralising and fusion-inhibitory activity against both RSV subtype A and B strains.
Palivizumab serum concentrations of approximately 30 μg/ml have been shown to produce a 99% reduction in pulmonary RSV replication in the cotton rat model.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Palivizumab binds a highly conserved region on the extracellular domain of mature RSV F protein, referred to as antigenic site II or A antigenic site, which encompasses amino acids 262 to 275. The antiviral activity of palivizumab was assessed in a microneutralization assay in which increasing concentrations of antibody were incubated with RSV prior to addition of the human epithelial cells HEp-2.
Original license holder
AstraZeneca AB
Marketing authorisation numbers
EU/1/99/117/001
Marketing authorisation holder
AstraZeneca AB
SE-151 85 Södertälje
Sweden
Name of the manufacturer of the biological active substance
Boehringer Ingelheim Pharma GmbH & Co. KG
D-88397 Biberach an der Riss
Germany

AstraZeneca Pharmaceuticals Limited Partnership (AZPLP)
660 MedImmune Court / 633 Research Court, Frederick, Maryland,
USA
Name and address of the manufacturer(s) responsible for batch releaseAbbVie S.r.l.
04011 Campoverde di Aprilia (LT)
Italy
Max shelf life
48 months
Storage conditions
2°C – 8°C
List of excipients
Powder:
Histidine
Glycine
Mannitol (E421)

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.